Kirk Peterson, MD
Family Medicine · Huxley, IANPI 1255391983
Payments from drug & device makers
Across 514 payments — averaging $1120.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$505K
- Shire North American Group Inc$66K
- AbbVie$765
- Johnson & Johnson$597
- Novo Nordisk$488
- Boehringer Ingelheim$476
- plus $3K from 26 others
What the payments were for
- Consulting fees$571,03699%
- Travel & lodging$810%
- Food & beverage$4,9321%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 183 | $505,035 |
| Shire North American Group Inc | 31 | $66,195 |
| AbbVie(2 entities) | 55 | $765 |
| Johnson & Johnson | 31 | $597 |
| Novo Nordisk | 33 | $488 |
| Boehringer Ingelheim | 31 | $476 |
| Amgen | 18 | $396 |
| AstraZeneca | 15 | $329 |
| GSK | 18 | $327 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $181 |
| Pfizer | 21 | $166 |
| Abbott | 6 | $135 |
| Astellas Pharma US Inc | 9 | $125 |
| Novartis | 7 | $122 |
| Merck | 8 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Stryker | 1 | $63 |
| Bristol Myers Squibb | 4 | $59 |
| Bayer | 3 | $56 |
| Lilly USA, LLC | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $47 |
| Therapeuticsmd, Inc. | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $20 |
| Kaleo, Inc. | 1 | $20 |
| Pacira Therapeutics, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$576,062 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $83,668 |
| OzempicSemaglutide | 79 | $79,438 |
| JardianceEmpagliflozin | 55 | $67,945 |
| XareltoRivaroxaban | 42 | $46,708 |
| JanuviaSitagliptin Phosphate | 14 | $21,398 |
| FarxigaDapagliflozin Propanediol | 19 | $15,560 |
| MyrbetriqMirabegron | 27 | $12,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,501 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $10,572 |
| EntrestoSacubitril/Valsartan | 12 | $10,079 |
| Victoza 3-PakLiraglutide | 12 | $9,208 |
| PremarinEstrogens, Conjugated | 14 | $8,172 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $8,014 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $3,550 |
| Levothyroxine Sodium | 357 | $3,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $166 | $91,840112 claims |
| Novo NordiskOzempic | $488 | $79,43879 claims |
| Boehringer IngelheimJardiance | $476 | $67,94555 claims |
| Johnson & JohnsonXarelto | $597 | $46,70842 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $327 | $22,07332 claims |
| MerckJanuvia | $104 | $21,39814 claims |
| AstraZenecaFarxiga | $329 | $15,56019 claims |
| Astellas Pharma US IncMyrbetriq | $125 | $12,27927 claims |
| NovartisEntresto | $122 | $10,07912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Huxley
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.